Search clinical trials for: Monalizumab/MEDI5257

Total 268 results

AstraZeneca
Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo

Recruiting

Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (DG-03)

Gastric Cancer

China, Spain, Korea, Republic of, Canada, Italy, Poland, Japan, United Kingdom, Brazil, Taiwan, United States, Germany, Netherlands, Russian Federation
MedImmune LLC

Active, not recruiting

A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors

Selected Advanced Solid Tumors

Italy, Spain, United States, France, Korea, Republic of, Taiwan, Australia, Netherlands, Portugal
AstraZeneca

Active, not recruiting

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN)

Metastatic Non-Small Cell Lung Cancer (NSCLC)

United States, Spain, Belgium, Poland, Taiwan, Thailand, Korea, Republic of, Russian Federation, Austria
Mayo Clinic
Genentech, Inc.

Withdrawn

Xolair (Omalizumab) for Treatment of Drug-induced Acute Tubulointerstitial Nephritis (AIN)

Acute Interstitial Nephritis

United States
Institute of Liver and Biliary Sciences, India

Completed

To Assess the Efficacy of Early Introduction of a Combination of Low Dose Vasopressin Analogue in Addition to Noradrenaline as a Vasopressor in Patients of Cirrhosis With Septic Shock

Cirrhosis With Septic Shock

India
Selina Gierer, D.O.

Withdrawn

Sustained Effect of Urticaria Remission With Relatively High Dose Vitamin D Supplementation After Omalizumab Discontinuation

Urticaria

United States
AstraZeneca
Daiichi Sankyo

Recruiting

Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (DL03)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Korea, Republic of, Italy, Poland, Malaysia, Taiwan, Thailand, United States, France, Netherlands, Philippines, Canada, Singapore, Spain, Turkey, Australia, Belgium, Israel
Ming-He Huang
University of Texas; Shantou University Medical College

Withdrawn

Concomitant Milrinone and Esmolol Treatment in Patients With Acute Myocardial Infarction (COMET-AMI)

Myocardial Reperfusion Injury

China
GlaxoSmithKline

Completed

Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients

Asthma

United States, Argentina, France, Germany, Spain, Canada, Sweden, Netherlands, Belgium
Novartis Pharmaceuticals

Terminated

An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)

Cystic Fibrosis | Allergic Bronchopulmonary Aspergillosis

United Kingdom, Germany, Belgium, Italy, Netherlands
Novartis Pharmaceuticals

Terminated

Study to Assess the Efficacy and Safety of Omalizumab Treatment on ICS Reduction for Severe IgE-mediated Asthma (MEXIC)

Severe IgE-mediated Asthma

Mexico
The Christie NHS Foundation Trust
University of Manchester

Withdrawn

A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer (IMpALA)

Breast Cancer
Shanghai Zhongshan Hospital

Not yet recruiting

A Prospective Study on Optimizing Treatment for ABPA

Allergic Bronchopulmonary Aspergillosis
Fundación Academia Española de Dermatología

Recruiting

Spanish Academy of Dermatology and Venereology Registry of Atopic Dermatitis Therapy (BIOBADATOP)

Dermatitis, Atopic

Spain
Novartis

Completed

Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma

Asthma

Brazil
Genentech, Inc.

Completed

A Safety Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic Despite Treatment With H1 Antihistamines, H2 Blockers, and/or Leukotriene Receptor Antagonists

Chronic Idiopathic Urticaria

Germany, United Kingdom, United States, Switzerland, Australia, New Zealand, Poland, Singapore
AstraZeneca
Daiichi Sankyo

Recruiting

Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Gastric Cancer | Colorectal Cancer | Ovarian Cancer | Endometrial Cancer | Urothelial Cancer | Biliary Tract Cancer | Metastatic Castration-resistant Prostate Cancer

Spain, China, Korea, Republic of, Canada, Italy, Poland, Turkey, United Kingdom, Japan, Taiwan, United States, France, Germany, Switzerland
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), The ARCHON-1 Trial

Stage III Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Unresectable Lung Non-Small Cell Carcinoma | Locally Advanced Lung Non-Small Cell Carcinoma | Locally Recurrent Lung Non-Small Cell Carcinoma

United States

Search clinical trials for: Monalizumab/MEDI5257

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations